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Abstract
Background: Diclofenac is a nonsteroidal anti-inflammatory drug which is available as prescription
(RX) and over-the-counter (OTC) medication for the systemic and topical treatment of painful and
inflammatory conditions such as arthritis and back pain. This study was undertaken to investigate
the distribution and retention of diclofenac and/or its metabolites in inflamed tissues, using the
carrageenan-induced inflammation model and quantitative whole body autoradiography in rats.
Methods: [14C]diclofenac sodium was administrated as a single 2 mg/kg oral dose 1 h after
injection of carrageenan into one front and one hind footpads and subcutaneously into the dorsum
of the neck of rats. A control animal received saline injections. Three carrageenan-treated rats and
one control rat were sacrificed at 1, 4, 8, and 24 h after [14C]diclofenac sodium administration
(total of 4 rats/time point). The carcasses were immediately snap-frozen and prepared for
cryosectioning. Lengthwise whole-body sections (40 m thick), including all major tissues, were
obtained from different levels across the body. The tissue concentrations of total radiolabeled
components were determined using quantitative autoradioluminography.
Results:  The radioactivity patterns demonstrated that diclofenac and/or its metabolites
preferentially distributed into the inflamed tissues. In unharmed tissues the distribution was similar
in control and treated animals. The exposure, based on the areas under the tissue concentration
versus time (AUC0-tlast), was 26 and 53 fold higher in the inflamed neck and inflamed footpads of
treated animals than in control rats; the exposures in unharmed tissues were similar in the treated
and control rats, and the AUC0-tlast was 17 fold higher in the inflamed paws than in the non inflamed
footpads of the carrageenan-treated rats. The higher exposure in the inflamed tissues may be
explained partly to the fact that the elimination of total radiolabeled components from inflamed
tissues (t1/2 = 6 h) appeared lower than from the corresponding unharmed tissues (t1/2 = 2 h).
Conclusion: This animal study demonstrated that diclofenac and/or its metabolites were rapidly
and preferentially taken up and retained in inflamed tissues. Although there were theoretical
considerations that mildly acidic NSAID may show some preferential distribution in inflamed
tissues there was no clear experimental proof for diclofenac until the present study.
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Background
Diclofenac belongs to the non steroidal anti-inflamma-
tory class of drugs (NSAIDS) and is widely used in the
treatment of moderate pain and inflammation, which are
common symptoms of various diseases, including arthri-
tis [1]. Diclofenac acts by inhibiting cyclooxygenases
(COX), which is an enzyme that converts arachidonic acid
into prostaglandins (PGs), thromboxanes and prostacyc-
lins [2,3]. The COX-1 isoenzyme is constitutively
expressed in all tissues [4] and its activation leads to the
production of prostaglandins involved in maintenance of
organs systems such as protection of the stomach wall or
for the kidney function. Prostaglandin in the gastric and
intestinal mucosa stimulates the secretion of mucus and
bicarbonate which protect the gastrointestinal tract
against acidity and digestive enzymes [5]. In contrast,
COX-2 is almost undetectable in most tissues under nor-
mal physiological conditions [6-8], but is induced when
there is a damage in the body, leading to the production
of PGs. When proinflammatory cytokines are produced,
COX-2 is expressed de novo in the inflamed tissue result-
ing in PGs formation, which mediates pain, fever and
inflammation [9]. NSAID can inhibit both COX isoen-
zymes, but diclofenac demonstrates some selectivity
towards COX-2 inhibition [10]. Efficacy of oral diclofenac
intake for relieving pain and inflammation or fever has
been demonstrated in several clinical studies with both
low dose available over-the-counter or at higher dose
available by prescription [11-15].
The present study aimed to investigate the relative distri-
bution of diclofenac in inflamed and normal tissues in an
animal model. It used radiolabeled drug that allowed the
to visualize the temporal distribution of total components
and to assess their concentrations in the various tissues by
means of quantitative whole-body autoradiography
(QWBA). Knowledge of the time course of the distribu-
tion of diclofenac in various organs is important in ration-
alizing the dosing schedule for various indications.
An inflammation model in rats was used in which rats
were injected in the footpads with carrageenan, a muco-
polysaccharide isolated from Irish sea moss. The model
allows confirmation of the anti-inflammatory and analge-
sic effects of drugs such as acetylsalicylic acid, hydrocorti-
sone or phenylbutazone at oral doses that are
representative for their clinical use in rheumatic diseases
[16]. Diclofenac, also, has been shown to be effective in
this rat model after an oral single dose of 2 mg/kg, the
dose that was selected for this pharmacokinetic study
[17].
Methods
Chemicals
[14C]diclofenac sodium was provided by American Radi-
olabeled Compounds (101 Arc Dr, St Louis, MO 63146,
USA) with a specific activity of 172 Ci/mg (50–60 mCi/
mmole, 6.4 MBq/mg). Non-labelled diclofenac sodium
supplied  in house was used to dilute the radiolabeled
material.
-carrageenan (article n° 22049-25G) was bought from
Sigma-Aldrich (Buchs, Switzerland).
Animals
Sixteen male pigmented Long Evans rats, 8 weeks old,
weighing 230 ± 25 g, obtained from Charles River
(Raleigh, NC, USA) were used. They had free access to
rodent chow (Provimi Kliba SA, CH-4303 Kaiseraugst)
and tap water during the entire study.
Dose formulation
For dosing, 5.6 mg of cold diclofenac sodium and 4.4366
g of the radioactive solution above (corresponding to
2.5662 mg of [14C]diclofenac sodium) were dissolved in
40.038 g of 0.9% saline. The dose, 2 mg/kg b.w. of
[14C]diclofenac sodium which has been reported to be the
ED40 in this animal model [17], was given p.o. by gavage
at 10 mL/kg in 0.9% saline. The radioactive dose was 4.11
MBq/kg b.w.
Experimental design
Twelve rats were subjected to an acute local inflammatory
reaction by subplantar injection with 0.1 mL of 1% w/v of
carrageenan in 0.9% saline into the left front footpad pad
and the left hind footpad and into the nape of the neck
(0.4 ml of the solution and 0.4 ml air given subcutane-
ously). The other 4 rats (control group) received 0.9%
saline into the same sites and at same volumes. The ani-
mals were slightly anesthetized with a 3% isoflurane/oxy-
gen mixture before the injection.
One hour after carrageenan or saline injection, all animals
received a single 2 mg/kg oral dose of [14C]diclofenac
sodium. Blood (50 L) was sampled from each animal
shortly prior to sacrifice by sublingual puncture for QWBA
validation purposes.
Liquid scintillation counting (LSC)
Radioactivity in aliquots of the [14C]diclofenac sodium
administration solution and of blood was determined by
LSC in a Liquid Scintillation System 2500 TR (Packard
Instr. Co., Meriden, CT, USA). For quench correction, the
external standard ratio method was used. Quench correc-
tion curves were established by means of sealed standards
(Packard Instr. Co.). Samples were prepared for analysis
as described [18]. The limit of detection (LOD) for deter-BMC Pharmacology 2009, 9:5 http://www.biomedcentral.com/1471-2210/9/5
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mination of radioactivity was defined as the 1.8-fold of
the total background count.
Quantitative whole-body autoradioluminography 
(QWBA)
Three treated rats and one control rat were used per time
point. They were euthanized with an overdose of isoflu-
rane at 1, 4, 8, and 24 h after dosing and thereafter imme-
diately deep-frozen for approx. 30 min into an n-hexane/
dry ice mixture kept at -70°C. The carcasses were rapidly
shaven and the paws removed. The carcasses and the paws
were then stored at a temperature below -20°C, and all
subsequent procedures were performed at temperatures
below -20°C to minimize diffusion of radiolabeled mate-
rial in the tissues/matrices.
Sectioning procedures
The frozen carcasses and paws were embedded in a mold
on a microtome stage by adding an ice-cold aqueous solu-
tion of 2% sodium carboxymethylcellulose (CMC). The
embedding block was frozen for approx. 30 min in an n-
hexane/dry ice mixture at -70°C followed by temperature
stabilization overnight in a -20°C freezer. The animals
were sectioned using a CM 3600 PLC cryomicrotome
(Leica Microsystems GmbH, D-Nussloch) according to
the method of Ullberg [19]. Several sagittal 40 m thick
whole-body sections were taken at varying depths, based
on sectioning of the requisite organs, tissues and body flu-
ids. Similarly, several 40 m thick sections were taken at
varying depths from the paws. A block of 14C radiolabeled
standards, prepared in blood and assayed by liquid scin-
tillation counting, was sectioned in the same manner and
on the same day as the rats were sectioned.
The sections were dehydrated in the cryomicrotome for 48
h at -30°C. Thereafter, they were labelled using radioac-
tive ink specifying the test compound, radiolabel, proto-
col number, dose route, animal strain, time of sacrifice
and number of section, resulting in a permanent label on
each section and phosphor image autoradiogram.
Imaging procedure
The whole-body autoradiograms were obtained by means
of the autoradioluminography method [20]. Tissue/
matrix and standard sections were placed in direct contact
with Fuji BASIII Imaging plates (Fuji Photo Film Co. Ltd.,
J-Tokyo) for 3 days at room temperature in a lead shielded
box in order to minimize the increase of the background
signal. The duration of the exposure was chosen to allow
detection of approx. 1 dpm/mg. At the end of the expo-
sure, the sections were separated from the plates, and the
plates were first kept for 3–5 min in the dark. They were
then transferred into a Fuji BAS 2000 TR phosphor-imager
(Fuji Photo Film Co. Ltd.) and scanned at a 100 m scan-
ning step with a 1024 gradation to produce an autoradio-
gram.
For reporting, selected sections were re-exposed onto SR
screens (Perkin Elmer, formerly Packard Instr., Meriden,
CN, USA) for 3 days at room temperature and scanned at
a 42 m scanning step in a ®Cyclone (Packard Instr.) phos-
phor-imager. The image files were processed using the
Adobe Photoshop Elements 2.0 software (Adobe Systems
Incorporated, San Jose, California, USA).
Determination of the tissue/matrix concentrations of total 
radiolabeled components
The concentrations of total radiolabeled components in
the tissues/matrices were determined by comparative den-
sitometry and digital analysis of the autoradiogram. The
radioactivity concentrations were calculated from the
curve generated from the calibration samples present on
the image plate and were expressed as nanomoles/gram of
tissue/matrix [21]. The resulting photo-stimulated light
data files were corrected by subtracting the background
and processed electronically with the help of a MCID/
Elite (Version 6.0) image analyzer (Imaging Research, St.
Catherines, Ontario, Canada). The calibration standards
were prepared from fresh whole rat blood and a stock
solution of a [14C]-labelled compound. Up to seven cali-
bration concentrations were prepared at concentrations of
2–4000 dpm/mg for 14C which encompass the range of
concentrations typically observed in a standard whole-
body autoradiography study. To assess the actual concen-
trations in the calibration standard samples, duplicate
100 L samples of spiked blood were counted for total
radioactivity in a liquid scintillation counter. These values
were defined as the actual concentrations and used to gen-
erate a calibration curve during digital analysis.
Quality control (section thickness homogeneity and
reproducibility checks) was performed by analyzing the
radioactivity concentration in the liver on each section. In
addition, the concentrations of radioactivity as deter-
mined by QWBA in blood were compared to the corre-
sponding ones determined by LSC (blood samples
collected from each animal shortly prior to sacrifice).
The limit of detection (LOD) was set equal to the mean of
background (n = 10) + 3 SD (standard deviations of the
individual values). The quantification limit (LOQ) was
empirically taken as 3￿LOD. The size of the areas used to
determine the background value was normalized to that
of the blood standards used to establish the calibration
curve. Under the conditions of this study, the LOD and
LOQ amounted to 0.034 and 0.10 nmol/g, respectively.BMC Pharmacology 2009, 9:5 http://www.biomedcentral.com/1471-2210/9/5
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Tissue/matrix distribution of radioactivity
The peak concentrations of radioactivity Cmax and time of
peak concentration tmax were recorded as observed. The
AUC(0-tlast) and t1/2 were calculated for those tissues/
matrices where sufficient quantifiable data points were
available. The AUC(0-tlast) were calculated using the linear
trapezoidal rule. The t1/2 was taken as ln(2)/z where z
(terminal elimination rate constant) was the slope of the
log linear line from the at least 3 last measurable data
points. All calculations were performed using the compu-
ter program WinNonlin®  (Professional 5.0) (Pharsight
Corp., Mountain View, CA, USA). The ratios of tissue/
matrix to blood Cmax and AUC(0-tlast) values were also
reported where possible.
Residual radioactivity in the body at 24 h after dosing
In order to estimate the overall residual radioactivity in
the body at 24 h after dosing, the mean concentrations of
total radiolabeled components over the entire section of
at least 6 sections per rat (one per sectioning level) were
determined as described above and converted into percent
of the administered dose by taking into account the
weight of the animals, the specific activity of the adminis-
tration formulations, the volume administered and the
actual doses.
Results
Distribution in tissues
Analysis of the whole body autoradiograms as shown in
Figure 1 allowed to determine concentrations of
diclofenac related material in the various tissues. Table 1
summarizes the values obtained at 1, 4, 8, and 24 h after
dosing of [14C]diclofenac sodium.
At 1 h after dosing, the distribution of total radiolabeled
components in the treated rats was mainly vascular, with
concentrations higher than in blood (mean of 1.6 nmol/
g) being found only in the bile, kidney, oesophagus and
liver (means of 34.0 to 4.5 nmol/g). Concentrations
around 1 nmol/g were found in the lung, tooth pulp,
adrenal cortex, penis, heart, and thyroid gland (means of
1.2 to 0.86 nmol/g), as well as in the inflamed footpads
(1.0 nmol/g). The mean concentrations of total radiola-
beled components in the neck and non-inflamed foot-
pads amounted to 0.79 nmol/g and 0.16 nmol/g,
respectively. The lowest concentrations of total radiola-
beled components were detected in the bone mineral,
brain, cartilage, lens, vitreous body, white fat, seminal ves-
icle, and spinal chord (traces). No radioactivity was
detected in the blood vessel wall and hair (LOD: 0.034
nmol/g).
The distribution pattern and overall concentrations in the
treated rats at 4 h and 8 h after dosing were quite similar
to those at 1 h after dosing, with the exception of the high
concentration found at 4 h after dosing in the penis. At 4
h after dosing, the bile, kidney, liver, penis, and oesopha-
gus (means of 34 to 3.5 nmol/g) showed higher concen-
trations than blood. The mean concentrations of total
radiolabeled components in the inflamed nape neck
inflamed footpads and non-inflamed footpads amounted
to 1.2, 1.3 and 0.15 nmol/g, respectively at 4 h after dos-
ing, and to 1.3 and 0.84 nmol/g and to traces, respectively,
at 8 h after dosing.
At 24 h after dosing, concentrations of total radiolabeled
components above the quantification limit (0.10 nmol/g)
were found in the treated rats only in the neck (applica-
tion site), bile, blood, kidney, liver, lung, penis, preputial
gland, and tooth pulp (means of 1.7 to 0.12 nmol/g). The
mean levels in the neck (application site) and inflamed
footpads amounted to 0.20 nmol/g and to traces, respec-
tively. No radioactivity was detected in the control foot-
pads.
The distribution patterns of radioactivity in the control
rats were similar to those in the treated animals, and are
therefore not described in detail. However the overall tis-
sue concentrations in the control rats appeared to be
slightly lower than in the treated animals.
Pharmacokinetics parameters
As shown in Table 2, the maximal concentration (Cmax)
was reached within 4 to 8 h (tmax) after dosing in the
inflamed footpads and the nape of the neck while in the
corresponding unharmed tissues tmax was at 1 h. Com-
pound related material was eliminated from most tissues
with a half-life (t1/2) of about 6 h. An even more rapid
elimination, with t1/2 of about 2 h, was observed from
control footpads of treated rats and from corresponding
unharmed tissues.
Uptake of total radiolabeled components into the 
inflamed tissues
Figure 1B and data from Table 3 clearly show that the con-
centrations of total radiolabeled components were higher
in the inflamed footpads and inflamed nape neck of the
treated animals than in the control animals. The ratio of
the AUC0-tlast  between the treated and control rats
amounted to 26 and 53 for the inflamed neck and foot-
pads, respectively, whereas in others tissues this ratio
ranged between 0.8 and 1.4. When compared in the same
animal the AUC in the inflamed footpads was 17 fold
higher than in the non inflamed footpads (Figure 1B;
Table 3).
Residual radioactivity in the body
Residual radioactivity in the body at 24 h after dosing
amounted to a mean of 1.4 nmol/g in the treated rats andBMC Pharmacology 2009, 9:5 http://www.biomedcentral.com/1471-2210/9/5
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Table 1: Tissue concentrations of total radiolabeled components at 1, 4, 8 and 24 h after oral administration of [14C]diclofenac sodium 
at a dose of 2 mg/kg to male rats injected with carrageenan (T) or saline (C) into the left front footpad and the left hind paw. 
Concentration of total radiolabeled components (nmol/g)
1 hour 4 hours 8 hours 24 hours
Tissue T C T C T C T C
Injection site nape neck 0.79 ± 0.12 0.18 1.20 ± 0.30 tc 1.30 ± 0.10 tc 0.20 ± 0.04 nd
Untreated footpads 0.16 ± 0.04 0.20 0.15 ± 0.10 0.20 tc nd nd nd
Injection site footpads 1.00 ± 0.23 0.12 1.30 ± 0.5 nd 0.84 ± 0.10 nd tc nd
Adrenal (cortex) 1.00 ± 0.32 0.29 0.94 ± 0.40 0.87 0.61 ± 0.10 0.59 tc nd
Bile 34.00 ± 6.25 20.00 34.00 ± 16.40 12.00 15.00 ± 3.40 7.50 1.60 ± 0.22 1.40
Blood 1.60 ± 0.27 1.00 2.20 ± 1.10 1.90 1.50 ± 0.20 1.20 0.15 ± 0.02 0.11
B o n e  m i n e r a l t c t ct ct c t c t c n a n a
B r a i n t c t ct ct c t c n a t c n a
Cartilage tc tc tc tc tc na na na
Eye (lens) tc tc tc tc tc tc tc na
Eye (vitreous body) tc tc tc tc tc tc tc na
Fat (brown) 0.69 ± 0.13 0.45 0.73 ± 0.30 0.81 0.46 ± 0.10 0.32 tc na
Fat (white) tc tc 0.12 0.15 tc tc tc na
Heart 0.86 ± 0.13 0.52 1.00 ± 0.50 1.00 0.68 ± 0.10 0.56 tc na
Kidney 11.00 ± 1.81 5.20 17.0 ± 5.50 11.00 9.10 ± 1.60 7.9 1.70 ± 0.09 1.20
Liver 4.50 ± 0.85 3.50 5.40 ± 1.10 3.90 3.0 ± 0.60 2.1 0.46 ± 0.05 0.31
Lung 1.20 ± 0.14 0.69 1.50 ± 0.70 1.30 1.00 ± 0.10 1.0 0.12 ± 0.01 0.10
Muscle 0.17 ± 0.04 0.11 0.22 ± 0.10 0.16 0.13 ± 0.01 0.12 tc T
Oesophagus 5.00 ± 1.03 9.20 3.50 ± 1.43 1.50 0.33 ± 0.15 0.39 na na
Penis 0.95 ± 0.15 0.42 7.00 ± 5.27 1.10 1.20 ± 0.11 0.65 0.27 ± 0.08 0.17
Seminal vesicle tc tc tc tc tc tc na nd
Spinal Cord tc tc tc tc tc tc na nd
Thyroid glands 0.86 ± 0.21 0.59 0.58 ± 0.11 0.60 0.46 ± 0.03 0.44 tc tc
Tooth pulp 1.20 ± 0.03 0.76 1.20 ± 0.23 1.00 1.00 ± 0.12 0.98 0.13 ± 0.04 0.10
na: not applicable, nd: not detected (< limit of detection 0.034 nmol/g), tc: Traces (between limit of detection and limit of quantification (0.10 nmol/
g))
Values are mean ± standard deviation (SD)for the T (n = 3) and mean value in C (n = 1).BMC Pharmacology 2009, 9:5 http://www.biomedcentral.com/1471-2210/9/5
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to 1.0 nmol/g in the control rat, corresponding to approx.
22% and 19% of the dose, respectively.
Discussion
The overall distribution patterns of total radiolabeled
components in the unharmed tissues were comparable in
animals injected with saline or with carrageenan, at all
time points investigated. The highest concentrations
throughout the study were found at 1 and 4 h after dosing
in the bile, kidney and liver, showing the biliary and renal
excretion of this compound and its metabolites, in agree-
ment with previous findings [22]. The concentration of
total radiolabeled components in the oesophagus in ani-
mals sacrificed at 1 hour after dosing was quite high,
which may be related to the oral dosing procedure.
[14C]diclofenac and/or its metabolites had the tendency
to reach higher concentrations in the inflamed footpads
and inflamed nape neck in the carrageenan injected ani-
mals when compared with the non-inflamed footpads
from either the same animal or the control animal. This
latter was mainly used to evaluate if the saline injection,
alone, might induce inflammation. However the results of
Table 1 exclude this assumption as accumulation of radi-
olabeled components was similar between saline injected
and non injected footpads from either the same control
animal (C) or from the treated animal (T).
The highest concentration of total radiolabeled compo-
nents in the inflamed footpads was observed 4 h after
injection of carrageenan. This is in accordance with a pre-
vious publication reporting that in this acute inflamma-
tion model COX-2 expression peaked at 1 h with maximal
PGs production after 2 to 4 h as a result of the increased
cyclooxygenases activity [23]. Depending of the site of
local carrageenan injection, the kinetic profile of the radi-
oactivity concentration was slightly different, which corre-
lates with a previous study showing that carrageenan
Selected whole-body autoradiograms of treated rats at 4 h in the whole animal (A), and in the injected footpads of the treated  and the control animal (B) after a 2 mg/kg oral dose of [14C]diclofenac sodium Figure 1
Selected whole-body autoradiograms of treated rats at 4 h in the whole animal (A), and in the injected foot-
pads of the treated and the control animal (B) after a 2 mg/kg oral dose of [14C]diclofenac sodium. The white 
areas correspond to the high radioactivity concentrations.
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Table 2: Pharmacokinetic parameters of total radiolabeled components in selected tissues/matrices, calculated from the radioactivity 
concentrations determined by QWBA after a 2 mg/kg oral dose of [14C]diclofenac sodium in treated rats (n = 3 animals/time point) 
and in control rats (n = 1 animal/time point).
Treated rats
(Carrageenan injected)
tmax (h) Cmax (nmol/g) AUC(0-tlast) (h*(nmol/g)) tlast (h) t1/2 (h)
Control footpads 1 0.16 0.92 8 1.80
Inflamed footpads 4 1.30 16.00 24 5.30
Inflamed nape neck 8 1.30 20.00 24 7.10
Blood 4 2.20 27.00 24 5.10
Kidney (cortex) 4 9.80 105.00 24 5.20
Liver 4 5.40 62.00 24 5.70
Control rats
(Saline injected)
tmax (h) Cmax (nmol/g) AUC(0-tlast) (h*(nmol/g)) tlast (h) t1/2 (h)
Control footpads 1 0.20 1.1 8 2.60
Injected footpads 1 0.12 0.30 4 1.60
Injected nape neck 1 0.18 0.77 8 2.90
Blood 4 1.90 22.00 24 4.90
Kidney (cortex) 4 8.20 88.00 24 5.30
Liver 4 4.00 45.00 24 5.50
Table 3: AUC ratios in selected tissues of treated (T; carrageenan injected) and control (C; saline injected) rats after a 2 mg/kg p.o. 
dose of [14C]diclofenac sodium. 
AUC(0-tlast) h*(nmol/g) Treated group T Control group C Ratio T/C
Control footpads 0.92* 1.10 0.82
Injected footpads 16.00* 0.30 53.00
Injected nape neck 20.00 0.77 26.00
Blood 27.00 22.00 1.20
Kidney (cortex) 105.00 88.00 1.20
Liver 62.00 45.00 1.40
The ratio in the treated group between the injected footpads and the control footpads (*) amounts to 17.BMC Pharmacology 2009, 9:5 http://www.biomedcentral.com/1471-2210/9/5
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elicits response which differs over time when injected at
different sites in the same rat [24].
Using autoradiography techniques, several studies have
shown that acidic NSAIDs preferentially accumulate in
acidic compartment, such as the stomach [25], kidney
[25] and inflamed tissues [26,27]. As shown in Figure 2
diclofenac sodium with its carboxylic acid group has a
pKa of 4.6 and belongs to the class of weak acidic drugs,
which may show increased lipophilicity in acidic com-
partment, leading to higher concentrations in cell mem-
branes [27,28]. In addition, the weak acidic properties of
NSAID as well as the bipolar lipophilic and hydrophilic
physico-chemistry of these drugs enable them to bind to a
high degree to plasma proteins in vivo [29]. This is due to
the high concentration of the fatty acid transporting pro-
tein albumin [30]. Subsequently these drugs are distrib-
uted mainly in the blood compartment. Therefore it is
suggested that the drug would be found in highly vascu-
larised tissues such as liver, lung, penis, preputial gland,
tooth pulp, which is supported by the current data (Table
1). In contrast, only traces of radioactivity were detected in
eyes, brain, seminal vesicle, and the spinal cord, as well as
the bone mineral and the cartilage which lack vascularisa-
tion. Higher accumulation of total radiolabeled compo-
nents was detected in the kidney, which might not be
dependent on the blood flow because plasma proteins are
not filtrated through the glomerulus. It would be assumed
that free diclofenac and its metabolites might be taken up
by the kidney through organic anion transporter (OAT)
on membrane of the renal proximal tubular cells [31].
Excretion of drugs is mainly through the hepatobiliary or
the renal routes but both pathways are complementary
each other. Drugs bound to plasma proteins are elimi-
nated through the bile while the kidney eliminates more
hydrophilic compounds and generally less bound to pro-
teins. Therefore the difference in physicochemical proper-
ties of diclofenac and its metabolites might result in
difference in affinity for membrane transporters or for
plasma proteins. This is translated in the present study by
the observation of an increased concentration of radiola-
beled components in the kidney and the bile (Table 1).
In the non inflamed part of the neck and the control foot-
pads, blood vessels density is low and no inflammation
was induced by the remote injection of carrageenan. Sub-
sequently the clearance of the drug or its related com-
pound from these tissues was rapid as shown in Table 2.
The present data consolidate the observation of Brune
[27], reporting that the capillary damage due to inflam-
mation results in plasma protein accumulation and con-
comitantly accumulation of the drug bound to these
proteins, causing an elevated drug concentration around
the leaky capillary. This raises the question whether this
protein/drug complex might be efficient in inhibiting the
COX-2 enzyme. Recent results from an in vitro study dem-
onstrated that increasing plasma protein did not affect the
potency of diclofenac to inhibit the COX-2 activity [32]
which might support the view that the anti-inflammatory
effect of protein-bound diclofenac is comparable to the
free drug. Brune has proposed that the local acid microen-
vironment caused by inflammation might favour uptake
of the neutral chemical form of diclofenac into the cell
membrane and into the cytoplasm of cell, where binding
to COX-2 enzymes may occur. [33].
Conclusion
This study allowed to assess the concentrations of
diclofenac and/or its metabolites in the tissues up to 24
hour after oral administration, emphasizing that binding
of the drug to plasma proteins, hence tissue perfusion, is
a key factor in distribution of diclofenac to its site of
action or to the hepato-biliary system. By contrast, metab-
olism of diclofenac, resulting in more hydrophilic com-
pounds that are less bound to plasma proteins, might lead
in higher uptake in the kidney by membrane transporter
proteins.
Though there were theoretical considerations that mildly
acidic NSAID may show some preferential distribution in
inflamed tissues, there was no clear experimental proof
for diclofenac until the present study.
Chemical structure of diclofenac sodium which acidic group  is circled Figure 2
Chemical structure of diclofenac sodium which acidic 
group is circled.
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